Global Health Investment Corporation

THE CORPORATION IS ORGANIZED AND SHALL BE OPERATED EXCLUSIVELY FOR SOCIAL (CONTINUED SCHEDULE O) (CONTINUED FROM FORM 990, PAGE 1 PART I) WELFARE PURPOSES WITHIN THE MEANING OF SECTION 501(C)(4) OF THE INTERNAL REVENUE CODE OF 1986, AS IT BE AMENDED, INCLUDING THE RELIEF OF THE POOR AND DISTRESSED OR OF THE UNDERPRIVILEGED; THE PROMOTION OF SOCIAL WELFARE AND THE LESSENING OF THE BURDENS OF GOVERNMENT. IN FURTHERANCE OF THESE PURPOSES, THE CORPORATION MAY SEEK WAYS TO PROVIDE AFFORDABLE FINANCING TO SUPPORT THE DEVELOPMENT OF THERAPEUTIC DRUGS & TREATMENTS, VACCINES, PREVENTATIVES, DIAGNOSTICS, AND OTHER TECHNOLOGIES, PRODUCTS OR SERVICES TO ADDRESS GLOBAL HEALTH CHALLENGES, INCLUDING WITHOUT LIMITATION, SUPPORTING THE DEVELOPMENT OF MEDICAL COUNTERMEASURES AND TECHNOLOGIES THAT CAN HELP ADDRESS THREATS TO GLOBAL HEALTH SECURITY, ALL TO PROMOTE THE SOCIAL WELFARE OF ALL POPULATIONS.

ACHIEVING FINANCIAL CLOSE OF THE GLOBAL HEALTH INVESTMENT FUND I ON 19 DECEMBER 2013, WITH CAPITAL COMMITMENTS OF $108,365,000. THE ORGANIZATION SERVES AS GENERAL PARTNER/MANAGING MEMBER OF THE GLOBAL HEALTH INVESTMENT FUND, AND ALSO PROVIDED A CAPITAL COMMITMENT TO THE FUND ALONGSIDE THE OTHER LIMITED PARTNERS. THE FUND'S CAPITAL WAS INVESTED INTO TWELVE PORTFOLIO INVESTMENTS DURING YEARS 2012-2018. THE ORGANIZATION MANAGED THE FUND'S PORTFOLIO COMPANY INVESTMENTS, RESULTING IN REVENUE TO THE FUND AND DISTRIBUTIONS TO THE ORGANIZATION AND THE OTHER LIMITED PARTNERS OF THE FUND. (CONTINUED SCHEDULE O) (CONTINUED FROM PART III, 4A) IN 2019, THE ORGANIZATION MADE AN INVESTMENT AS LIMITED PARTNER IN THE ADJUVANT CAPITAL GLOBAL HEALTH INVESTMENT FUND DE, IN THE AMOUNT OF $22 MILLION.IN 2021, THE ORGANIZATION MADE AN INVESTMENT AS LIMITED PARTNER IN THE WOMEN'S AND CHILDREN'S HEALTH TECHNOLOGY FUND, IN THE AMOUNT OF $10 MILLION. THE ORGANIZATION ENTERED INTO A TEN-YEAR AGREEMENT WITH U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE'S BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY ("BARDA") TO CARRY OUT ACTIVITIES THAT FOSTER AND ACCELERATE THE DEVELOPMENT AND INNOVATION OF MEDICAL COUNTERMEASURES. THE AGREEMENT, UNLIKE TYPICAL FEE FOR SERVICE OR COST REIMBURSEMENT PROCUREMENT GRANTS, WAS STRUCTURED AS AN OTHER TRANSACTION AGREEMENT ("OTA") OF WHICH BARDA, WITH THE AUTHORITY UNDER APPLICABLE LAW, MAY ENTER INTO TRANSACTIONS OTHER THAN PROCUREMENT CONTRACTS, GRANTS, COOPERATIVE AGREEMENTS, AND ARE NOT SUBJECT TO FEDERAL ACQUISITION REGULATION. DURING 2021, THE ORGANIZATION RECEIVED $16.6 MILLION IN FUNDING FROM BARDA UNDER THE OTA, FOR ACTIVITIES TO BE CONDUCTED BY THE ORGANIZATION PURSUANT TO THE OTA. THE ORGANIZATION ESTABLISHED A WHOLLY OWNED DELAWARE LIMITED LIABILITY COMPANY, THE GHIC GLOBAL HEALTH SECURITY PORTFOLIO, LLC (THE "GHS PORTFOLIO LLC"), TO MAKE VENTURE INVESTMENTS IN BIOTECHNOLOGY COMPANIES AND OTHER ORGANIZATIONS DEVELOPING TECHNOLOGIES THAT FALL WITHIN THE MISSION SCOPE OF THE OTA ACTIVITIES. IN 2021, THE ORGANIZATION MADE ITS INITIAL INVESTMENT WITH BARDA FUNDING, THROUGH THE GHS PORTFOLIO LLC, IN THE PRIVATE EQUITY SECURITIES OF BIOLINQ. IN 2022, THE ORGANIZATION RECEIVED AN ADDITIONAL $68.8 MILLION IN FUNDING FROM BARDA PURSUANT TO THE OTA. THE ORGANIZATION ALSO ENTERED INTO A STRATEGIC COLLABORATION ARRANGEMENT WITH THE MITRE CORPORATION, PURSUANT TO WHICH MITRE AGREED TO PROVIDE THE ORGANIZATION WITH UP TO $10 MILLION TO BE CO-INVESTED BY GHIC, ALONGSIDE BARDA PROVIDED FUNDING, IN VENTURE INVESTMENTS MADE BY THE ORGANIZATION PURSUANT TO THE OTA. DURING THE COURSE OF 2022, THE ORGANIZATION (THROUGH THE GHS PORTFOLIO LLC) MADE TEN INVESTMENTS OF PRIVATE EQUITY SECURITIES IN BIOTECHNOLOGY COMPANIES WITH BARDA AND MITRE PROVIDED CAPITAL. AT DECEMBER 31, 2022, THE TOTAL AMOUNT INVESTED BY THE GHS PORTFOLIO LLC IN THE ELEVEN PORTFOLIO COMPANY INVESTMENTS WAS $39 MILLION.